These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39044524)

  • 1. The Insulin Sensitizer KBP-336 Prevents Diabetes-Induced Cognitive decline in ZDF Rats.
    Larsen AT; Mohamed KE; Petersen EA; Karsdal MA; Henriksen K
    J Prev Alzheimers Dis; 2024; 11(4):1122-1131. PubMed ID: 39044524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes.
    Larsen AT; Mohamed KE; Melander SA; Karsdal MA; Henriksen K
    Am J Physiol Endocrinol Metab; 2024 Aug; 327(2):E145-E154. PubMed ID: 38864815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats.
    Melander SA; Møller AL; Mohamed KE; Rasmussen DGK; Genovese F; Karsdal MA; Henriksen K; Larsen AT
    Am J Physiol Endocrinol Metab; 2023 Nov; 325(5):E529-E539. PubMed ID: 37792041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss.
    Larsen AT; Melander SA; Sonne N; Bredtoft E; Al-Rubai M; Karsdal MA; Henriksen K
    Biomed Pharmacother; 2023 Aug; 164():114969. PubMed ID: 37269811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long-acting dual amylin and calcitonin receptor agonist improves insulin-mediated glycaemic control and controls body weight.
    Melander SA; Larsen AT; Karsdal MA; Henriksen K
    Br J Pharmacol; 2024 Jun; 181(12):1829-1842. PubMed ID: 38378168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats.
    Andreassen KV; Feigh M; Hjuler ST; Gydesen S; Henriksen JE; Beck-Nielsen H; Christiansen C; Karsdal MA; Henriksen K
    Am J Physiol Endocrinol Metab; 2014 Jul; 307(1):E24-33. PubMed ID: 24801386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats.
    Andreassen KV; Larsen AT; Sonne N; Mohamed KE; Karsdal MA; Henriksen K
    Mol Metab; 2021 Nov; 53():101282. PubMed ID: 34214708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Dual Amylin and Calcitonin Receptor Agonist, KBP-066, Induces an Equally Potent Weight Loss Across a Broad Dose Range While Higher Doses May Further Improve Insulin Action.
    Sonne N; Larsen AT; Andreassen KV; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2020 Apr; 373(1):92-102. PubMed ID: 31992608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.
    Larsen AT; Mohamed KE; Sonne N; Bredtoft E; Andersen F; Karsdal MA; Henriksen K
    Biomed Pharmacother; 2022 Dec; 156():113842. PubMed ID: 36242844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Calcitonin Receptor Plays a Major Role in Glucose Regulation as a Function of Dual Amylin and Calcitonin Receptor Agonist Therapy.
    Larsen AT; Sonne N; Andreassen KV; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2020 Jul; 374(1):74-83. PubMed ID: 32317372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss.
    Thorsø Larsen A; Karsdal MA; Henriksen K
    Eur J Pharmacol; 2023 Sep; 954():175837. PubMed ID: 37329973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Dual Amylin- and Calcitonin-Receptor Agonist KBP-042 Works as Adjunct to Metformin on Fasting Hyperglycemia and HbA1c in a Rat Model of Type 2 Diabetes.
    Hjuler ST; Gydesen S; Andreassen KV; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2017 Jul; 362(1):24-30. PubMed ID: 28438778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin.
    Melander SA; Katri A; Karsdal MA; Henriksen K
    Eur J Pharmacol; 2023 Jan; 938():175397. PubMed ID: 36414113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Exposure Profile on the Efficacy of Dual Amylin and Calcitonin Receptor Agonist Therapy.
    Sonne N; Larsen AT; Karsdal MA; Henriksen K
    Biomedicines; 2022 Sep; 10(10):. PubMed ID: 36289629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
    Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
    Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy.
    Larsen AT; Sonne N; Andreassen KV; Gehring K; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2019 Jul; 370(1):35-43. PubMed ID: 31028106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose Frequency Optimization of the Dual Amylin and Calcitonin Receptor Agonist KBP-088: Long-Lasting Improvement in Food Preference and Body Weight Loss.
    Larsen AT; Sonne N; Andreassen KV; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2020 May; 373(2):269-278. PubMed ID: 32071103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog.
    Gydesen S; Andreassen KV; Hjuler ST; Hellgren LI; Karsdal MA; Henriksen K
    Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E598-E607. PubMed ID: 28292761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight.
    Gydesen S; Andreassen KV; Hjuler ST; Christensen JM; Karsdal MA; Henriksen K
    Am J Physiol Endocrinol Metab; 2016 May; 310(10):E821-7. PubMed ID: 26908506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference.
    Gydesen S; Hjuler ST; Freving Z; Andreassen KV; Sonne N; Hellgren LI; Karsdal MA; Henriksen K
    Br J Pharmacol; 2017 Apr; 174(7):591-602. PubMed ID: 28109166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.